Winner of the Ernst & Young Entrepreneur of the Year for Science and Technology for both Scotland and at the UK National finals in 2005, Jim has had a successful international career in the pharmaceutical and biotechnology industries. A Biochemist and Pharmacologist by training, Jim developed his early career in blue-chip organisations including Organon, Roche and Alcan in many parts of the world progressing from the research bench to business management before returning to Scotland in 1999. Since then he has utilised this experience to contribute widely to the exciting life sciences industry there. Jim was instrumental in the formation and development of more than 10 companies in the sector and has successfully exited from 3 of these companies, including the highly acclaimed sale of Haptogen to Wyeth, one of the world’s top pharmaceutical companies. Jim is now expanding his work with early stage Life Science companies hopefully picking the “winners” of the future in this key sector of the Scottish economy. He is a Global Scot, an Ambassador of the Saltire Fellowship and was the recipient of the 2010 Outstanding Contribution to Scottish Life Science award.

Liam joined Sistemic in February 2021 as VP, Scientific Operations. Liam is responsible for organizing and co-ordinating the wet lab work, bioinformatics analysis and final output for client projects in both Research and Development and Diagnostic Testing. In addition, he is responsible for coordinating the quality aspect of the business. Prior to joining Sistemic, Liam worked for over 10 years in molecular and cell biology, immunology and microbiology in academia. Working across diverse biological areas, as well as, the drug discovery process, has provided Liam with an in-depth biological knowledge and expertise of the drug discovery process across a wide range of disease/therapeutic areas including chronic infectious diseases, immunology and the renal system. A key area of expertise for Liam, with direct relevance in the cell therapy space, is the identification and application of translational efficacy/potency biomarkers, both pre-clinically and clinically.